01:03 , Jan 4, 2019 |  BC Week In Review  |  Company News

Tetra grants Shionogi Asian rights to Alzheimer's/fragile X candidate

Shionogi & Co. Ltd. (Tokyo:4507) received from Tetra Discovery Partners LLC (Grand Rapids, Mich.) exclusive rights in Japan, Korea and Taiwan to develop BPN14770 to treat brain disorders associated with dementia, including Alzheimer's disease and...
19:00 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Tetra reports preliminary Phase I data for AD candidate BPN14770

Tetra Discovery Partners LLC (Grand Rapids, Mich.) reported preliminary data from a Phase I trial in 45 healthy elderly volunteers showing that twice-daily 10 and 20 mg oral doses of Alzheimer's disease candidate BPN14770 for...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

BPN14770: Phase I started

Tetra began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of oral BPN14770 in about 48 healthy volunteers. Tetra Discovery Partners LLC , Grand Rapids, Mich.   Product: BPN14770   Business:...
01:33 , Dec 31, 2015 |  BC Extra  |  Clinical News

Tetra candidate backed by NIH's Blueprint enters clinic

Tetra Discovery Partners LLC (Grand Rapids, Mich.) began Phase I testing of BPN14770 , the first candidate funded by NIH's Blueprint Neurotherapeutics Network (BPN) to reach the clinic. The negative allosteric modulator of phosphodiesterase-4D (...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Company News

Tetra Discovery, Broad Institute of MIT and Harvard deal

Tetra partnered with the institute's Stanley Center for Psychiatric Diseases to evaluate the ability of the company's phosphodiesterase-4D (PDE-4D) inhibitor to improve cognition in the center's proprietary schizophrenia genetic models. Tetra is evaluating PDE-4 inhibitors...
07:00 , Sep 10, 2012 |  BioCentury  |  Emerging Company Profile

Putting a Lid on PDE-4

Efforts to directly inhibit phosphodiesterase-4 's active site to treat neurological indications have failed due to dose-limiting toxicities. Tetra Discovery Partners LLC is trying to take side effects out of the equation with allosteric inhibitors...
08:00 , Feb 6, 2006 |  BioCentury  |  Product Development

Breathless opportunities

Treatment of asthma has remained essentially unchanged for years and focuses on alleviating symptoms rather than disease modification. In large part, the state of the art reflects inertia on the part of the dominant big...
01:16 , Oct 7, 2005 |  BC Extra  |  Clinical News

PDE-4 inhibitors linked to heart failure in mice

Research published in Cell linked phosphodiesterase-4 (PDE-4) inhibitors to heart failure and cardiac arrhythmias in mice. In the study, inactivating the PDE-4D gene resulted in progressive cardiomyopathy, accelerated heart failure and cardiac arrhythmias. A number...
07:00 , Sep 29, 2003 |  BC Week In Review  |  Company News

deCode, Roche other research news

Researchers published in Nature Genetics that the gene encoding PDE-4D is associated with stroke, including forms of the disease that are associated with atherosclerosis. Researchers identified 3 main haplotypes - wild-type, at-risk and protective -...
07:00 , Sep 8, 2003 |  BioCentury  |  Regulation

Making a better PDE-4 inhibitor

Choking on Ariflo Making a better PDE-4 inhibitor The rationale for targeting phosphodiesterase-4 (PDE-4) in chronic obstructive pulmonary disorder (COPD) is straightforward: it reduces inflammatory cell activity. But companies have had limited success in developing...